SparingVision

SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent drug candidate to treat retinitis pigmentosa, the most common inherited retinal d... Read more

Industries

Headquarters

Stage

Series B

Employees

11-50

Links

Org chart

Stéphane Boissel

CEO

Collapse

Chief Operating Officer

CMO

Myriam Marussig

COO

Florence Lorget

CDSO

CTO

CFO

General Counsel

Florence Paliargues

VP Portfolio Program Management

VP, Intellectual Property

Anne-Sophie Gautron

Director Translational Sciences

Teams

View all

Board of Directors

19 members

Leadership Team

6 members

CEO and Executive Team

5 members

Discover similar companies

Voyager Therapeutics

Cambridge, United States · Post IPO Equity

Coave Therapeutics

Paris, France

Flow Robotics

Copenhagen, Denmark

GENFIT

Loos, France · Post IPO Equity

Mnemo Therapeutics

Paris, France · Series A

Sutro Biopharma

South San Francisco, United States · Post IPO Equity

Biophytis

Paris, France · Post IPO Debt

Illumina

San Diego, United States

Transgene

Illkirch, France

MassBio

Cambridge, United States

DBV Technologies

Montrouge, France · Post IPO Equity

F2G

Manchester, United Kingdom · Private Equity

Two candidates

The Org
helps you hire
great candidates

It takes less than ten minutes to set up your company page.
It’s free to use - try it out today.